Microarrays Coming of Age in Cardiovascular Medicine Standards, Predictions, and Biology⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Ginsburg, Geoffrey S. et al.
EM
A
S
G
D
D
H
m
h
o
b
t
p
m
s
i
o
p
d
d
a
s
l
u
m
u
r
h
e
m
d
i
d
e
b
t
c
e
v
t
v
A
C
N
Journal of the American College of Cardiology Vol. 48, No. 8, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Pt
m
s
c
v
h
p
w
a
t
s
t
a
t
l
p
t
m
T
t
w
d
o
c
m
m
d
a
v
a
e
m
c
c
i
r
s
p
o
h
v
t
b
e
t
e
d
m
p
fi
m
f
t
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.025DITORIAL COMMENT
icroarrays Coming of
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eoffrey S. Ginsburg, MD, PHD, FACC,†‡
avid Seo, MD,†‡ Camille Frazier, MD‡
urham, North Carolina
igh-density microarray, or so-called “gene chip,” experi-
ents, wherein the levels of expression of the 25,000
uman genes is measured using RNA isolated from a tissue
r cell, is now commonplace and uniquely adaptable to a
road array of medical and biologic questions. For example,
he application of microarray analyses to cancer has provided
henotypic detail never before appreciated using traditional
ethods of analysis by illuminating patterns of gene expres-
ion or “gene expression signatures.” These signatures have
n turn provided novel insights into molecular mechanisms
f disease and laid the groundwork for the development of
redictors for future health risks. In 1999, in one of the first
emonstrations of the use of gene expression microarrays to
See page 1610
issect the molecular architecture of leukemia, investigators
t MIT identified a signature of 50 genes out of 6,817
urveyed that could distinguish between acute myeloid
eukemia and acute lymphoblastic leukemia (1). Since then,
nique gene expression profiles have classified hematologic
alignancies (2,3) as well as solid tumors (4) and have been
sed to predict survival (5), clinical outcome (6), recurrence
isk (7), and response to therapy (8). Other areas of biology
ave followed suit, and there are now some tantalizing
xamples of the benefits of this technology in cardiovascular
edicine that illustrate the opportunity to uncover subtle
istinctions in biological states. Such distinctions may be
mportant for understanding the complexity of disease and
eveloping novel diagnostics and therapeutics (9,10).
Cardiomyopathy is often a diagnosis in search of an
tiology. Histologic classification is frequently nonspecific,
ut if the etiology could be determined, important prognos-
ic information and therapeutic options might be more
learly defined (11). Access to myocardial tissue from
ndomyocardial biopsy and tissue cores at the time of left
entricular assist device placement or during transplanta-
ion, has provided an opportunity heretofore never available
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Duke Institute for Genome Sciences and Policy and the ‡Division ofp
ardiology, Department of Medicine, Duke University Medical Center, Durham,
orth Carolina.o subclassify and categorize this constellation of diseases
olecularly using genome-wide expression analysis. Several
tudies have examined the use of microarray technologies to
lassify failing versus nonfailing hearts (12,13), dilated
ersus ischemic cardiomyopathy (14), and dilated versus
ypertrophic cardiomyopathy (15). One notable study com-
ared myocardial tissue from patients with end-stage disease
ith that from newly diagnosed cardiomyopathy to develop
classifier that correctly predicted the etiology of disease in
he tissue with about 90% accuracy (14). In most of these
tudies, however, the numbers of patients were small and
here were significant differences in methods for data
nalysis, in the regions of the myocardium sampled, and in
he handling of the tissues at the time of harvest. Nonethe-
ess, large lists of deregulated genes were found, and various
athways involving sarcomeric and cytoskeletal proteins,
ranscriptional regulation of cell signaling, mitochondrial
etabolism, and inflammation appeared to be prominent.
his leaves open the question as to which of these genes
ruly reflect the biology of the underlying myopathy and
hich reflect differences in clinical variables such as disease
uration, age, gender, ethnicity, and medications at the time
f tissue harvest of biopsy. Or, one might ask, do these
hanges in gene expression result from systematic experi-
ental factors such as the choice of microarray platform, the
ethods of tissue handling, or the mechanical or oxidative
amage sustained during sample collection, processing,
nd/or storage? Finally, only one of these studies verified or
alidated the results in a second unrelated population to
ssess for type I error or model overfitting. Therefore, the
xact meaning of the gene expression signatures obtained in
ost of the studies is unclear.
In many cases investigators fail to recognize the extreme
omplexity of the disease tissue under study as well as the
omplexity of the microarray experiments themselves. These
ssues have led to the development of standards for microar-
ay experimental information (16). Moreover, they empha-
ize the point that a research design that accounts for
otential systematic errors is the most important component
f gene expression-based investigations. Given the likeli-
ood that gene expression analyses will increase in cardio-
ascular medicine, it is imperative that the data represent
he biology of the disease and not noise or artifacts induced
y experimental design. “Expression noise” (i.e., the inher-
nt gene expression variation that does not correlate with
he biology being studied and is introduced by or during the
xperimental procedure) has recently been the subject of
ebate and discussion among avid users of gene expression
icroarrays (17). Expression noise can obscure informative
atterns of gene expression (resulting in false negative
ndings), but because most computational approaches to
icroarray analysis are focused on finding true associations,
alse positive findings are usually of greater concern, even in
he presence of profound noise. Indeed, as the experimental
rotocols used to generate RNA from myocardial or vascu-
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October 17, 2006:1618–20 Editorial Commentar tissues for arrays may also be significantly confounded by
schemia, hypoxia, and hemodynamic stressors introduced
uring the tissue procurement and isolation, how can we be
ure that the resulting data reflect the ischemic response in
ivo versus the ischemic response ex vivo?
In this issue of the Journal, Barth et al. (18) have
ddressed the issue of confounders in microarray exper-
ments probing end-stage cardiomyopathy. In addition
hey have explored the biologic significance of the genes
dentified by array experiments using gene ontologies to
escribe putative mechanisms underlying the different
linically classified forms of heart failure. Using 2 datasets
rom 2 different gene expression analysis platforms
cDNA spotted arrays and oligonucleotide arrays) in their
wn laboratory, Barth et al. (18) accessed a large number
f samples from nonfailing and dilated cardiomyopathy
nd purposefully selected different regions of the ventricle
septum and left ventricular subendocardium) to keep
heir data as discrete and clean as possible. They also
nalyzed datasets from 2 additional laboratories available
hrough the Gene Expression Omnibus microarray data-
ase (available through the National Center for Biotech-
ology Information). Thus, a large number of samples
as available that allowed them to identify transcriptional
ignatures that could distinguish between dilated cardio-
yopathy, ischemic cardiomyopathy, and nonfailing
earts. They were able to develop training sets of classi-
ers that had 90% accuracy in 3 of the 4 datasets. They
erived a 27-gene classifier from one of these and used it
o categorize the etiology of cardiomyopathy in each of
he 3 remaining sets, for which also 90% accuracy was
chieved. Notably, this signature contains brain natri-
retic peptide (BNP) and BNP-related genes, sarcomeric
tructural proteins, and genes involved in the cell cycle,
ellular proliferation, and apoptosis, consistent with pub-
ished reports of biologic markers and molecular path-
ays known to be deregulated in cardiomyopathy. How-
ver, individual BNP-related genes were unable to
lassify the etiology of the myopathy in the absence of the
omplete set of genes, thereby illustrating the power and
tility of this approach. In addition, a robust gene
ignature of immune response was seen across all the
atasets that deserves further exploration. But because
he hearts under study were end-stage, whether these
echanisms or pathways are relevant to the earlier stages
f disease and its progression remains unclear. And
lthough these observations are not necessarily profound,
hey deserve recognition for the meticulous attention to
etail that went into the authors’ experimental design, as
llustrated by the reproducibility of their work in the
ultiple datasets from different sources. This approach
hould serve as a guidepost for subsequent gene
xpression-based studies in cardiovascular disease.
So where do we go from here? As Barth et al. (18)
oint out, there is a need to explore tissues other than the
yocardium for potential diagnostic precision in heartailure for all the reasons outlined in the preceding as well
s for practical issues of tissue accessibility. Gene expres-
ion profiling from blood RNA may hold promise in this
egard, because it has already been demonstrated that
ndividual proinflammatory cytokine RNA transcripts
rom blood monocytes can discriminate between different
orms of cardiomyopathy (19). Moreover, microarray
nalyses of RNA from blood have led to a noninvasive
est that can classify heart transplant patients into low-
nd high-risk categories for cardiac rejection before
linical symptoms or biopsy evidence appear (20). At the
nd of the day, whether the RNA is from diseased tissue
r from a blood surrogate, if the right standards are in
lace, gene expression profiling holds tremendous prom-
se for classifying clinical phenotypes, developing prog-
ostic predictors and, most importantly, providing novel
nbiased insights into the mechanisms underlying heart
isease. Barth et al. (18) have made an excellent start and
et a standard for others to follow in cardiovascular
enomic medicine.
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